Trials / Completed
CompletedNCT00166504
Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Patients With Primary Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea. The primary hypothesis being tested is that daily administration of Vytorin will result in a greater reduction of low density lipoprotein cholesterol (LDL-C) concentration from baseline after 6 weeks treatment compared to atorvastatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ezetimibe (+) simvastatin | simvastatin/ezetimibe 10/20 mg |
| DRUG | atorvastatin | atorvastatin 10 mg |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-09-14
- Last updated
- 2024-05-22
- Results posted
- 2008-11-05
Source: ClinicalTrials.gov record NCT00166504. Inclusion in this directory is not an endorsement.